High-cost biologics for rheumatoid arthritis- how are payer-led cost-taming strategies impacting brand uptake in the united states?

May 1, 2015, 00:00 AM
10.1016/j.jval.2015.03.961
https://www.valueinhealthjournal.com/article/S1098-3015(15)01018-9/fulltext
Section Title : Muscular-Skeletal Disorders
Section Order : 408
First Page : A166
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)01018-9&doi=10.1016/j.jval.2015.03.961
HEOR Topics :
Tags :
Regions :